An ANA (antinuclear antibody) test looks for antinuclear antibodies in your blood. If the test finds antinuclear antibodies in your blood, it may mean you have an autoimmune disorder. An autoimmune disorder causes your immune system to attack your own cells, tissues, and/or organs by mistake. These disorders can cause serious health problems.
Antibodies are proteins that your immune system makes to fight foreign substances like viruses and bacteria. But an antinuclear antibody attacks your own healthy cells instead. It's called "antinuclear" because it targets the nucleus (center) of the cells.
The global Antinuclear Antibody (ANA) Test market is projected to reach US$ 1580.9 million in 2029, increasing from US$ 949.4 million in 2022, with the CAGR of 7.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antinuclear Antibody (ANA) Test market research.
Rising prevalence of autoimmune diseases among people, across the globe is expected to drive antinuclear antibody test market in the forecast time period. Antinuclear antibody tests are becoming more and more popular as a way to diagnose autoimmune diseases such rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, and many more. These factors are anticipated to propel the antinuclear antibody test market growth in near future.
The antinuclear antibody testing market is expanding as a result of technological developments as well as rising R&D expenditures for the creation of fresh products or testing methodologies. Also, the market is expected to accelerate in coming days due to growing government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. Additionally, the service and delivery capacity of the antinuclear antibody test kit is anticipated to increase due to the increased investment in start-ups delivering preventative healthcare tests. The aforementioned factors are projected to increase the antinuclear antibody test market opportunity over the coming years.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antinuclear Antibody (ANA) Test market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott
Bio-Rad Laboratories, Inc
ERBA Diagnostics, Inc
Trinity Biotech plc
Thermo Fisher Scientific, Inc
Antibodies, Inc
EUROIMMUN AG
Immuno Concepts
Inova Diagnostics
Zeus Scientific
Segment by Type
Reagents & Assay Kits
Systems
Software & Service
Segment by Application
Hospitals
Clinical Laboratories
Physician Office Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Antinuclear Antibody (ANA) Test report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antinuclear Antibody (ANA) Test Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Reagents & Assay Kits
1.2.3 Systems
1.2.4 Software & Service
1.3 Market by Application
1.3.1 Global Antinuclear Antibody (ANA) Test Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinical Laboratories
1.3.4 Physician Office Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antinuclear Antibody (ANA) Test Market Perspective (2018-2029)
2.2 Antinuclear Antibody (ANA) Test Growth Trends by Region
2.2.1 Global Antinuclear Antibody (ANA) Test Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antinuclear Antibody (ANA) Test Historic Market Size by Region (2018-2023)
2.2.3 Antinuclear Antibody (ANA) Test Forecasted Market Size by Region (2024-2029)
2.3 Antinuclear Antibody (ANA) Test Market Dynamics
2.3.1 Antinuclear Antibody (ANA) Test Industry Trends
2.3.2 Antinuclear Antibody (ANA) Test Market Drivers
2.3.3 Antinuclear Antibody (ANA) Test Market Challenges
2.3.4 Antinuclear Antibody (ANA) Test Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antinuclear Antibody (ANA) Test Players by Revenue
3.1.1 Global Top Antinuclear Antibody (ANA) Test Players by Revenue (2018-2023)
3.1.2 Global Antinuclear Antibody (ANA) Test Revenue Market Share by Players (2018-2023)
3.2 Global Antinuclear Antibody (ANA) Test Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antinuclear Antibody (ANA) Test Revenue
3.4 Global Antinuclear Antibody (ANA) Test Market Concentration Ratio
3.4.1 Global Antinuclear Antibody (ANA) Test Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antinuclear Antibody (ANA) Test Revenue in 2022
3.5 Antinuclear Antibody (ANA) Test Key Players Head office and Area Served
3.6 Key Players Antinuclear Antibody (ANA) Test Product Solution and Service
3.7 Date of Enter into Antinuclear Antibody (ANA) Test Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antinuclear Antibody (ANA) Test Breakdown Data by Type
4.1 Global Antinuclear Antibody (ANA) Test Historic Market Size by Type (2018-2023)
4.2 Global Antinuclear Antibody (ANA) Test Forecasted Market Size by Type (2024-2029)
5 Antinuclear Antibody (ANA) Test Breakdown Data by Application
5.1 Global Antinuclear Antibody (ANA) Test Historic Market Size by Application (2018-2023)
5.2 Global Antinuclear Antibody (ANA) Test Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Antinuclear Antibody (ANA) Test Market Size (2018-2029)
6.2 North America Antinuclear Antibody (ANA) Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antinuclear Antibody (ANA) Test Market Size by Country (2018-2023)
6.4 North America Antinuclear Antibody (ANA) Test Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antinuclear Antibody (ANA) Test Market Size (2018-2029)
7.2 Europe Antinuclear Antibody (ANA) Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antinuclear Antibody (ANA) Test Market Size by Country (2018-2023)
7.4 Europe Antinuclear Antibody (ANA) Test Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antinuclear Antibody (ANA) Test Market Size (2018-2029)
8.2 Asia-Pacific Antinuclear Antibody (ANA) Test Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antinuclear Antibody (ANA) Test Market Size by Region (2018-2023)
8.4 Asia-Pacific Antinuclear Antibody (ANA) Test Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antinuclear Antibody (ANA) Test Market Size (2018-2029)
9.2 Latin America Antinuclear Antibody (ANA) Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antinuclear Antibody (ANA) Test Market Size by Country (2018-2023)
9.4 Latin America Antinuclear Antibody (ANA) Test Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antinuclear Antibody (ANA) Test Market Size (2018-2029)
10.2 Middle East & Africa Antinuclear Antibody (ANA) Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antinuclear Antibody (ANA) Test Market Size by Country (2018-2023)
10.4 Middle East & Africa Antinuclear Antibody (ANA) Test Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Antinuclear Antibody (ANA) Test Introduction
11.1.4 Abbott Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.1.5 Abbott Recent Development
11.2 Bio-Rad Laboratories, Inc
11.2.1 Bio-Rad Laboratories, Inc Company Detail
11.2.2 Bio-Rad Laboratories, Inc Business Overview
11.2.3 Bio-Rad Laboratories, Inc Antinuclear Antibody (ANA) Test Introduction
11.2.4 Bio-Rad Laboratories, Inc Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.2.5 Bio-Rad Laboratories, Inc Recent Development
11.3 ERBA Diagnostics, Inc
11.3.1 ERBA Diagnostics, Inc Company Detail
11.3.2 ERBA Diagnostics, Inc Business Overview
11.3.3 ERBA Diagnostics, Inc Antinuclear Antibody (ANA) Test Introduction
11.3.4 ERBA Diagnostics, Inc Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.3.5 ERBA Diagnostics, Inc Recent Development
11.4 Trinity Biotech plc
11.4.1 Trinity Biotech plc Company Detail
11.4.2 Trinity Biotech plc Business Overview
11.4.3 Trinity Biotech plc Antinuclear Antibody (ANA) Test Introduction
11.4.4 Trinity Biotech plc Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.4.5 Trinity Biotech plc Recent Development
11.5 Thermo Fisher Scientific, Inc
11.5.1 Thermo Fisher Scientific, Inc Company Detail
11.5.2 Thermo Fisher Scientific, Inc Business Overview
11.5.3 Thermo Fisher Scientific, Inc Antinuclear Antibody (ANA) Test Introduction
11.5.4 Thermo Fisher Scientific, Inc Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.5.5 Thermo Fisher Scientific, Inc Recent Development
11.6 Antibodies, Inc
11.6.1 Antibodies, Inc Company Detail
11.6.2 Antibodies, Inc Business Overview
11.6.3 Antibodies, Inc Antinuclear Antibody (ANA) Test Introduction
11.6.4 Antibodies, Inc Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.6.5 Antibodies, Inc Recent Development
11.7 EUROIMMUN AG
11.7.1 EUROIMMUN AG Company Detail
11.7.2 EUROIMMUN AG Business Overview
11.7.3 EUROIMMUN AG Antinuclear Antibody (ANA) Test Introduction
11.7.4 EUROIMMUN AG Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.7.5 EUROIMMUN AG Recent Development
11.8 Immuno Concepts
11.8.1 Immuno Concepts Company Detail
11.8.2 Immuno Concepts Business Overview
11.8.3 Immuno Concepts Antinuclear Antibody (ANA) Test Introduction
11.8.4 Immuno Concepts Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.8.5 Immuno Concepts Recent Development
11.9 Inova Diagnostics
11.9.1 Inova Diagnostics Company Detail
11.9.2 Inova Diagnostics Business Overview
11.9.3 Inova Diagnostics Antinuclear Antibody (ANA) Test Introduction
11.9.4 Inova Diagnostics Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.9.5 Inova Diagnostics Recent Development
11.10 Zeus Scientific
11.10.1 Zeus Scientific Company Detail
11.10.2 Zeus Scientific Business Overview
11.10.3 Zeus Scientific Antinuclear Antibody (ANA) Test Introduction
11.10.4 Zeus Scientific Revenue in Antinuclear Antibody (ANA) Test Business (2018-2023)
11.10.5 Zeus Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott
Bio-Rad Laboratories, Inc
ERBA Diagnostics, Inc
Trinity Biotech plc
Thermo Fisher Scientific, Inc
Antibodies, Inc
EUROIMMUN AG
Immuno Concepts
Inova Diagnostics
Zeus Scientific
*If Applicable.